Medtronic plc (NYSE:MDT) has a beta value of 0.67 and has seen 1,465,621 shares traded in the recent trading session. The company, currently valued at $145.38 Billion, closed the recent trade at $107.8 per share which meant it gained $0.23 on the day or 0.21% during that session. The MDT stock price is -13.31% off its 52-week high price of $122.15 and 33.09% above the 52-week low of $72.13. If we look at the company’s 10-day average daily trading volume, we find that it stood at 4.13 Million shares traded. The 3-month trading volume is 4.91 Million shares.
The consensus among analysts is that Medtronic plc (MDT) is an Overweight stock at the moment, with a recommendation rating of 2. None of the analysts rate the stock as a Sell, while 2 rate it as Overweight. 6 out of 26 have rated it as a Hold, with 18 advising it as a Buy. None have rated the stock as Underweight. The expected earnings per share for the stock is $0.83.
Medtronic plc (NYSE:MDT) trade information
Sporting 0.21% in the green today, the stock has traded in the green over the last five days, with the highest price hit on Tuesday, Sep 15 when the MDT stock price touched $108.68 or saw a rise of 1.19%. Year-to-date, Medtronic plc shares have moved -5.34%, while the 5-day performance has seen it change 0.68%. Over the past 30 days, the shares of Medtronic plc (NYSE:MDT) have changed 6.63%. Short interest in the company has seen 7.29 Million shares shorted with days to cover at 1.48.
Wall Street analysts have a consensus price target for the stock at $117.73, which means that the shares’ value could jump 9.21% from current levels. The projected low price target is $110 while the price target rests at a high of $130. In that case, then, we find that the current price level is +20.59% off the targeted high while a plunge would see the stock lose 2.04% from current levels.
Medtronic plc (MDT) estimates and forecasts
Figures show that Medtronic plc shares have underperformed across the wider relevant industry. The company’s shares have gained +34.11% over the past 6 months, with this year growth rate of -13.94%, compared to 5.3% for the industry. Other than that, the company has, however, lowered its growth outlook for the 2020 fiscal year revenue. Growth estimates for the current quarter are -36.6% and -19.4% for the next quarter. Revenue growth from the last financial year stood is estimated to be +0.9%.
If we evaluate the company’s growth over the last 5-year and for the next 5-year period, we find that annual earnings growth was +7.7% over the past 5 years. Earnings growth for 2020 is a modest +2.3% while over the next 5 years, the company’s earnings are expected to increase by 9.41%.
Medtronic plc is expected to release its next earnings report between November 24 and November 24 this year, and investors are excited at the prospect of better dividends despite the company’s debt issue. The forward dividend is 2.32 at a share yield of 2.16%. The company’s dividend yield has gone up over the past 12 months, with a 5 Year Average Dividend Yield of 2.07%.
Medtronic plc (NYSE:MDT)’s Major holders
Insiders own 0.07% of the company shares, while shares held by institutions stand at 85.82% with a share float percentage of 85.88%. Investors are also buoyed by the number of investors in a company, with Medtronic plc having a total of 2420 institutions that hold shares in the company. The top two institutional holders are Vanguard Group, Inc. (The) with over 113.11 Million shares worth more than $10.37 Billion. As of June 29, 2020, Vanguard Group, Inc. (The) held 8.41% of shares outstanding.
The other major institutional holder is Blackrock Inc., with the holding of over 111.21 Million shares as of June 29, 2020. The firm’s total holdings are worth over $10.2 Billion and represent 8.27% of shares outstanding.
Also the top two Mutual Funds that are holding company’s shares are Vanguard Total Stock Market Index Fund and Vanguard 500 Index Fund. As of June 29, 2020, the former fund manager holds about 2.84% shares in the company for having 38193090 shares of worth $3.5 Billion while later fund manager owns 27.83 Million shares of worth $2.55 Billion as of June 29, 2020, which makes it owner of about 2.07% of company’s outstanding stock.